Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12620001300965
Ethics application status
Approved
Date submitted
23/04/2020
Date registered
1/12/2020
Date last updated
3/08/2025
Date data sharing statement initially provided
1/12/2020
Date results provided
3/08/2025
Type of registration
Retrospectively registered

Titles & IDs
Public title
Performance barriers for cochlear implant recipients
Scientific title
A prospective, multi-centre case-control trial examining factors that predict variable clinical performance in post lingual adult CI recipients
Secondary ID [1] 300849 0
Nil known
Universal Trial Number (UTN)
Trial acronym
PREVA
Linked study record

Health condition
Health condition(s) or problem(s) studied:
auditory sensitivity 316758 0
cochlear implant 316759 0
Condition category
Condition code
Ear 314986 314986 0 0
Deafness

Intervention/exposure
Study type
Observational
Patient registry
False
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
The purpose is to examine factors that predict variable clinical performance in post-lingual adult cochlear implant recipients. The approved medical device on test (AMDTs) include models CI24RE (CA), CI422, CI512, CI522, CI612, CI622, CI532, CI632. These AMDTs provide auditory sensation and sound perception by electrically stimulating the auditory nerve of a hearing-impaired ear for individuals aged 18 years and older who have clinically established postlinguistic bilateral or unilateral sensorineural hearing loss and who have compromised functional hearing with hearing aids or would receive no benefit with hearing aids. Typical preoperative threshold levels in the impaired ears demonstrate a pure-tone average of moderately severe to profound degree.
After screening, participants will attend three face-to-face, on-site visits with an optional fourth visit where tests will be administered by the qualified audiologist Site Investigators. Visit 1 will occur on the screening day where standard clinical tests, MAPping procedures, words in quiet and loud, sentences in noise, aided thresholds and digit triplet test will be done. Visit 2 will occur within 60 days of screening where standard tests IOI questionnaire and non-standard tests BP T-level (Psychophysical), BP C-levels, Language Independent Test (LIT), Quick Spectral Modulation Detection (QSMD), Amplitude Modulation Detection Threshold (AMDT), IPG Change, Polarity Effect (PE) NRT 4 point impedance and Voltage matrix/Trans Impedance matrix (TIM) will be done, and Visit 3 will be subsequent to Visit 2 but within 90 days of screening where standard tests MoCA and Vocab test and non-standard tests SMDT, PDQ at 65 dB SPL and 50 dB SPL, Polarity Effect (Psychophysical), Spread of Excitation (SOE), Refractory/Recovery and Stroop will be done. The optional 4th visit is for subjects who for some reason are unable to complete testing in three visits and for subjects who are tested on the outcome measures with a changed MAP. There will be an initial pilot phase with one three-hour session including screening to confirm that the diagnostic test measures are operating as intended and to confirm the time required to administer the tests. The first five subjects recruited from either site will participate in this pilot phase and will be included in the main study. The Pilot Visit non-standard tests are biopolar T-levels, Bipolar C- levels, Polarity Tests (Behavioural), AMDT, QSMD and time permitting 4 point impedance and SOE (ECAP). For the main phase, the screening/initial visit will occur on the same day followed by two follow-up visits. All visits are anticipated to be approximately three to four hours in duration. These sessions will include appropriate breaks for the recipient to prevent fatigue. Non-standard tests utilise software tools that are part of the standard battery to test measures that are not standard clinical test battery.
The fidelity to the tests will be assessed and monitored through Source Data Validation five times at each site throughout the study in accordance with Visit 1 will occur following the completion of the first 5 subjects, Visit 2 will occur following the completion of the first 25 subjects, Visit 3 will occur following the completion of the first 50 subjects, Visit 4 will occur following the completion of the first 75 subjects and the final close out monitoring visit will take place after the last subject has completed data collection.
There will 200 subjects enrolled in the study, with 100 enrolled at each of the two sites (60 poorer performers and 40 good performers). Subjects who withdraw from the study will be replaced. The enrolment period for the clinical investigation is anticipated to be 22 months from the time of first subject consent to enrolment of the last subject. The expected duration of each subject’s participation in the clinical investigation is up to two months from the time of informed consent through to the End of Study visit.
The design is mainly prospective. However, it incorporates collection of retrospective speech perception and imaging data. The latter will enable analysis of the potential influence of anatomical and surgical placement variability on CI outcomes.
Intervention code [1] 317176 0
Not applicable
Comparator / control treatment
No control group.
Control group
Uncontrolled

Outcomes
Primary outcome [1] 323305 0
Post-implantation aided thresholds at 250, 500, 1000, 2000, 3000, 4000 and 6000Hz at Visit 1.
Timepoint [1] 323305 0
At the same week as informed consent. Timepoint relative to participant is screening/baseline.
Primary outcome [2] 323306 0
Post-implantation phoneme discrimination in noise (LIT) at Visit 2-3.
Timepoint [2] 323306 0
Up to three months from the time of informed consent through to the End of Study visit. Timepoints relative to participants are 60 days, 90 days and 120 days (if optional 4th visit completed).
Primary outcome [3] 325504 0
Post-implantation phoneme discrimination in quiet (PDQ) at Visit 2-3.
Timepoint [3] 325504 0
Up to three months from the time of informed consent through to the End of Study visit. Timepoints relative to participants are 60 days, 90 days and 120 days (if optional 4th visit completed).
Secondary outcome [1] 381490 0
Post-implantation quick Spectral Modulation Detection (QSMD) at Visit 2-3. Note: This is the fourth primary outcome measure.
Timepoint [1] 381490 0
Up to three months from the time of informed consent through to the End of Study visit. Timepoints relative to participants are 60 days, 90 days and 120 days (if optional 4th visit completed).
Secondary outcome [2] 381491 0
Post-implantation amplitude modulation detection threshold (AMDT) at Visit 2-3. Note: This is the fifth primary outcome measure.
Timepoint [2] 381491 0
Up to three months from the time of informed consent through to the End of Study visit. Timepoints relative to participants are 60 days, 90 days and 120 days (if optional 4th visit completed).
Secondary outcome [3] 381492 0
Post-implantation word recognition in quiet score (consonant-nucleus-consonant (CNC) words test) at screening. Note: This is the sixth primary outcome measure.
Timepoint [3] 381492 0
At the same week as informed consent. Timepoint relative to participant is screening/baseline.
Secondary outcome [4] 381493 0
Difference in CI alone sentence in noise scores (Visit 1 minus pre-operative).
Timepoint [4] 381493 0
At the same week as informed consent. Timepoint relative to participant is screening/baseline.
Secondary outcome [5] 381494 0
Auditory sensitivity performance in visits 1-3 for perimodiolar and lateral wall electrode array subgroups.
Timepoint [5] 381494 0
Up to three months from the time of informed consent through to the End of Study visit. Timepoints relative to participants are screening/visit 1 at week 0, visit 2 (within 60 days of screening) and visit 3 (within 90 days of screening) and 120 days (if optional 4th visit is completed).
Secondary outcome [6] 381495 0
Relative performance on auditory sensitivity performance and word recognition in quiet.
Timepoint [6] 381495 0
Up to three months from the time of informed consent through to the End of Study visit. Timepoints relative to participants are screening/baseline, 60 days, 90 days 120 days (if optional 4th visit completed).
Secondary outcome [7] 388220 0
Sentence in noise scores in Visit 1 in the CI alone and best bilateral conditions.
Timepoint [7] 388220 0
At the same week as informed consent. Timepoint relative to participant is screening/baseline.
Secondary outcome [8] 388221 0
Relative performance on LIT versus word recognition in quiet at each of the two sites.
Timepoint [8] 388221 0
Up to three months from the time of informed consent through to the End of Study visit. Timepoints relative to participants are screening/baseline, 60 days, 90 days 120 days (if optional 4th visit completed).
Secondary outcome [9] 388224 0
Pre-operative PB max score on Freiburg words in quiet under headphones (MHH site only)
Timepoint [9] 388224 0
Pre-operative prior to cochlear implantation.

Eligibility
Key inclusion criteria
1. Minimum duration of cochlear implant experience of 12 months in the ear to be assessed
2. Implanted greater than or equal to 2007 in the ear to be assessed in the study.
3. Word recognition score in quiet at a conversational level that is either a) below the 35th percentile (“poorer”) or b) above the 65th percentile of the site’s implanted population (implanted greater than or equal to 2007) at the site AND greater than or equal to 10% higher than the pre-operative aided word score in the ear to be assessed in the study (“good”).
4. Pre-operative word score in the implanted ear to be assessed in the study less than or equal to 80%
5. 18 years of age or older at the time of implantation of the ear to be assessed in the study.
6. Appropriate pre- and post-operative imaging; specifically, pre-operative MRI, pre-operative CT and post-operative CT that allows sufficient resolution to identify individual electrode contacts.
7. Willingness to participate in and to comply with all requirements of the protocol.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1) Limited conditioning of the auditory pathway. Specifically, recipients to be excluded are those who were diagnosed with prelingual severe to profound hearing loss at less than or equal to 2 years of age AND meet at least one of the following criteria
i. Use non-speech based means as a primary mode of communication (for example, sign language)
ii. Have an aided post operative word score in quiet at 65 dB SPL in the implanted ear that is less than 5%
2) Diagnosed cognitive deficit deemed by the investigators to potentially impact outcomes
3) Restricted electrical frequency allocation table due to current use of combined electric-acoustic stimulation (either with or without amplification in the ear to be assessed)
4) Non-fluent in the language used for assessments at the investigational site
5) Additional handicaps that would prevent participation in evaluations
6) Unrealistic expectations on the part of the subject, regarding the possible benefits, risks and limitations that are inherent to the procedure and investigation
7) Investigator site personnel directly affiliated with this study and/or their immediate families; immediate family is defined as a spouse, parent, child, or sibling.
8) Cochlear employees or employees of Contract Research Organisations or contractors engaged by Cochlear for the purposes of this investigation.
9) Currently participating, or participated within the last 30 days, in another interventional clinical investigation/trial involving an investigational drug or device.

Study design
Purpose
Duration
Selection
Timing
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
Actual
22/10/2020
Date of last participant enrolment
Anticipated
Actual
22/02/2023
Date of last data collection
Anticipated
1/08/2022
Actual
28/03/2023
Sample size
Target
200
Accrual to date
Final
128
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment outside Australia
Country [1] 22452 0
Germany
State/province [1] 22452 0
Lower Saxony

Funding & Sponsors
Funding source category [1] 305304 0
Commercial sector/Industry
Name [1] 305304 0
Cochlear Limited
Country [1] 305304 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
Cochlear Limited
Address
1 University Avenue
Macquarie University
NSW 2109
Country
Australia
Secondary sponsor category [1] 305667 0
None
Name [1] 305667 0
Address [1] 305667 0
Country [1] 305667 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 305643 0
Royal Victorian Eye and Ear Hospital (RVEEH)
Ethics committee address [1] 305643 0
Ethics committee country [1] 305643 0
Australia
Date submitted for ethics approval [1] 305643 0
Approval date [1] 305643 0
26/03/2020
Ethics approval number [1] 305643 0
20/1457H

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 101062 0
Prof Robert Cowan
Address 101062 0
HEARnet Ltd 550 Swanston Street Carlton VIC 3053
Country 101062 0
Australia
Phone 101062 0
+61 03 90354710
Fax 101062 0
Email 101062 0
[email protected]
Contact person for public queries
Name 101063 0
Herah Hansji
Address 101063 0
Cochlear Limited 1 University Avenue Macquarie University NSW 2109
Country 101063 0
Australia
Phone 101063 0
+61 03 86623107
Fax 101063 0
Email 101063 0
[email protected]
Contact person for scientific queries
Name 101064 0
Pam Dawson
Address 101064 0
Cochlear Limited 1 University Avenue Macquarie University NSW 2109
Country 101064 0
Australia
Phone 101064 0
+61 0386623107
Fax 101064 0
Email 101064 0
[email protected]

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: Cochlear do not have an approved platform for public sharing of IPD collected in this study.



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
TypeIs Peer Reviewed?DOICitations or Other DetailsAttachment
Basic resultsNo PREVA_basic_results_final.docx
Study results articleYeshttps://doi.org/10.1177/23312165251347138 Dawson P, Fullerton A, Krishnamoorthi H, et al. A ... [More Details]

Documents added automatically
No additional documents have been identified.